Virion Therapeutics
Business Services · Delaware, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
7 Creek Bend Ct, Newark, Delaware, 19711...Phone Number
(800) 841-9303Website
www.viriontx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Virion Therapeutics
Virion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative T cell-based immunotherapies for cancer and chronic infectious diseases. The company employs genetically encoded checkpoint modifiers to enhance CD8 T cell responses, aiming to improve clinical outcomes and survival rates. Currently, they are enrolling human studies for their lead program, VRON-0200, targeting chronic HBV. Their approach combines checkpoint modifiers with optimized target antigens to create adaptable and accessible therapies.Explore more
Virion Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Virion Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Virion Therapeutics
Check out if Virion Therapeutics is spiking on competitors!
Product Launch: Get notified when Virion Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Virion Therapeutics has new funding data
Click to see if Virion Therapeutics had a recent Job posting/layoffs
Check if Virion Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Virion Therapeutics recently announced quarterly report
Virion Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Virion Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Virion Therapeutics
Compare insights from companies similar to Virion Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Virion Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Virion Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Virion Therapeutics.
Virion Therapeutics Tech Stack
A closer look at the technologies used by Virion Therapeutics
See more technologies
Virion Therapeutics News & Media
Virion Therapeutics Reports Positive Clinical Data with VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure, at APASL 2025 Global Liver Meeting
Highlights from the Data Presentation Safety, immunogenicity, and anti-HBV activity, presented in chronically HBV-infected patients following a single, prime-only, or a prime and boost, intramuscular injection of VRON-0200 Over 7,680 patient safety days (N=27), VRON-0200 was well...Virion Therapeutics Completes Enrollment of First 2 Cohorts of Phase 1b Chronic Hepatitis B Trial of VRON-0200 For HBV Functional Cure
Twenty-seven patients with Chronic Hepatitis B Virus infection (CHB) have now been dosed with VRON-0200 as a single (Prime), or Prime and Boost, intramuscular (i.m.) injection PHILADELPHIA, Jan. 10, 2025 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company,...Virion Therapeutics Reports First-Ever Clinical Responses with VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure, at AASLD's The Liver Meeting®
Highlights from the Data Presentation Ongoing safety (N=25) and immunogenicity (n=22), and first report of anti-HBV activity, presented in chronically HBV-infected patients following a single, prime-only intramuscular injection of VRON-0200 Over 4,952 patient safety days, VRON-0200 was...Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker presentation highlighting the first-ever human immunogenicity data from its novel checkpoint modifier immunotherapy for HBV functi
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Virion Therapeutics
Sign Up For FreeTo access detailed company insights
Virion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative T cell-based immunotherapies for cancer and chronic infectious diseases. The company employs genetically encoded checkpoint modifiers to enhance CD8 T cell responses, aiming to improve clinical outcomes and survival rates. Currently, they are enrollin... Read More
